Final analysis of a phase 3 trial in 308 patients with advanced anal squamous cell carcinoma: retifanlimab plus carboplatin-paclitaxel kept a PFS benefit v placebo (HR 0.62); key secondary OS HR 0.75 (95% CI 0.55-1.01), median 32.8 v 22.2 months.
RCTn = 308 patients
Rao et al. Survival outcomes in POD1UM-303/InterAACT-2: a phase III study of retifanlimab plus carboplatin-paclitaxel in first-line advanced squamous anal cancer